1. Academic Validation
  2. Selective Inhibition of PTP1B by New Anthraquinone Glycosides from Knoxia valerianoides

Selective Inhibition of PTP1B by New Anthraquinone Glycosides from Knoxia valerianoides

  • J Nat Prod. 2022 Nov 18. doi: 10.1021/acs.jnatprod.2c00879.
Zheng Zhang 1 Zhi-Peng Shang 1 Yan Jiang 1 Zhao-Xia Qu 1 Ren-Yong Yang 1 Jing Zhang 1 Ye-Xi Lin 1 Feng Zhao 1
Affiliations

Affiliation

  • 1 The Key Laboratory of Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine of China, School of Pharmacy, Binzhou Medical University, Yantai 264003, People's Republic of China.
Abstract

Protein tyrosine Phosphatase 1B (PTP1B) is highly validated as a therapeutic target for type 2 diabetes. However, active site-directed PTP1B inhibitors generally suffer from poor selectivity and bioavailability. Inspired by the identification of a unique anthraquinone-coumarin hybrid from Knoxia valerianoides exhibiting good specificity for PTP1B over the highly homologous T-cell protein tyrosine Phosphatase (TCPTP), further chemical investigation of this plant species led to the isolation of nine new anthraquinone glycosides (1-9) and two known ones (10 and 11). Structures were characterized by a combination of spectroscopic analyses and chemical methods. All compounds showed PTP1B inhibitory activities with IC50 values ranging from 1.05 to 13.74 μM. Compounds 4 and 8 exhibited greater than 64-fold selectivity over TCPTP. Enzyme kinetic studies revealed that compounds 4 and 7 behaved as mixed-type inhibitors. Docking studies predicted similar binding modes of these compounds at the allosteric site positioned between helices α3 and α6.

Figures
Products